Quoin Pharmaceuticals, Ltd. - American Depositary Shares QNRX 深 沪
等待开盘 08-02 09:30:00 美东时间
6.82
+0.120
+1.79%
华盛通- 最 高6.82
- 今 开6.70
- 成交量 2621股
- 最 低 6.67
- 昨 收 6.70
- 总市值 3443.91万
- 52周最高 54.95
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 5.01
- 委 比 0.00%
- 总股本 504.97万
- 历史最高 1417500.00
- 量 比 0.72
- 振 幅 2.24%
- 历史最低 5.824
- 每 手 1
- 风险率 7.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced it will release its second-quarter 2025 financial results before the market opens on August 7, 2025. The announcement will include an operational update and financial highlights. The company, focused on rare and orphan diseases, has four products in development targeting conditions like Netherton Syndrome and Epidermolysis Bullosa. For more details, visit www.quoinpharma.com or contact Michael M...
07-31 12:30
Quoin Pharmaceuticals Update Product Portfolio
Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East.QRX003 Peeling Skin Syndrome Clinical Program Continues Following
07-29 20:36
Quoin Pharmaceuticals CFO Departure Announcement
Quoin Pharmaceuticals ( ($QNRX) ) just unveiled an announcement. On July 3, 202...
07-09 05:29
Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases
Quoin Pharmaceuticals releases a new episode in its Netherton NOW series, featuring Professor Jemima Mellerio discussing the severe impact of Netherton Syndrome on infants and children. The video highlights the lack of effective treatments and the critical need for research. Quoin’s QRX003, a topical lotion, has received Rare Pediatric Disease Designation from the FDA, marking progress in addressing this orphan disease. The initiative aims to rai...
06-26 12:30
Quoin Pharmaceuticals Receives FDA Rare Pediatric Disease Designation For QRX003 To Treat Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration
06-24 20:36
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals Ltd. announced that the FDA has granted Rare Pediatric Disease (RPD) Designation for its lead asset, QRX003, for the treatment of Netherton Syndrome. This designation follows the EMA's Orphan Drug Designation for QRX003 in May 2025. Dr. Michael Myers, CEO of Quoin, expressed excitement about advancing QRX003 towards a New Drug Application as a potential first treatment for this severe genetic disease. The designation may qua...
06-24 12:30
Quoin Pharmaceuticals Updates Shareholder Proposal Deadlines
The latest update is out from Quoin Pharmaceuticals ( ($QNRX) ). Quoin Pharmace...
06-21 05:16
Quoin Pharmaceuticals Approves Executive Cash Bonuses
Quoin Pharmaceuticals ( ($QNRX) ) has issued an update. On May 29, 2025, Quoin ...
06-05 04:40
Quoin Pharmaceuticals shares are trading higher after the company announced it received FDA clearance to initiate a second whole-body QRX003 netherton syndrome clinical study.
Quoin Pharmaceuticals shares are trading higher after the company announced it ...
05-22 20:36
